OncLive TV

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Virginia G. Kaklamani, MD, discusses the use of adjuvant olaparib in germline BRCA1/2-mutant breast cancer.

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.

Edward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.

Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.

Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.

Shirish M. Gadgeel, MD, discusses the efficacy of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

Peter Kozuch, MD, discusses the role of circulating tumor DNA in colorectal cancer.

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss how they turned their leukemia career “lemons” into “lemonade.”